Ironwood Moves into China Via $150M AstraZeneca Deal

By Catherine ShafferStaff Writer

Tuesday, October 23, 2012

AstraZeneca plc will be Ironwood Pharmaceuticals Inc.'s development and commercialization partner for linaclotide in the vast China territory. Ironwood filed a clinical trial application with China's State Food and Drug Administration for a Phase III study of linaclotide in irritable bowel with constipation (IBS-C).